Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M De Boer

Showing results (701-710 of 719) with videos related to

Pageof 72
Sort By:
The Lancet. Oncology|September 8, 2025
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): 10-year clinical outcomes and post-hoc analysis by molecular classification from a randomised phase 3 trialCathalijne C B Post, Stephanie M de Boer, Melanie E Powell, et al.
Science Immunology|January 30, 2021
Steroid-resistant human inflammatory ILC2s are marked by CD45RO and elevated in type 2 respiratory diseasesEsmee K van der Ploeg, Korneliusz Golebski, Menno van Nimwegen, et al.
European Journal of Cancer (Oxford, England : 1990)|May 2, 2021
Clinical characteristics of subsequent histologically confirmed meningiomas in long-term childhood cancer survivors: A Dutch LATER studyLisanne C Verbruggen, Judith L Kok, Jop C Teepen, et al.
The Lancet. Oncology|May 3, 2024
Prognostic impact and causality of age on oncological outcomes in women with endometrial cancer: a multimethod analysis of the randomised PORTEC-1, PORTEC-2, and PORTEC-3 trialsFamke C Wakkerman, Jiqing Wu, Hein Putter, et al.
The Lancet. Oncology|February 17, 2018
Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trialStephanie M de Boer, Melanie E Powell, Linda Mileshkin, et al.
Journal of Occupational Rehabilitation|September 4, 2020
Effectiveness of a Tailored Work-Related Support Intervention for Patients Diagnosed with Gastrointestinal Cancer: A Multicenter Randomized Controlled TrialA C G N M Zaman, K M A J Tytgat, J H G Klinkenbijl, et al.
The Lancet. Oncology|July 27, 2019
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trialStephanie M de Boer, Melanie E Powell, Linda Mileshkin, et al.
Nature Medicine|April 15, 2026
An acetylated Tau-174 CSF biomarker discriminates between TDP-43 and tau pathology in patients with frontotemporal lobar degenerationMadison I J Honey, Yanaika S Hok-A-Hin, Elisabeth H Thijssen, et al.
International Journal of Radiation Oncology, Biology, Physics|November 1, 2020
Long-Term Toxicity and Health-Related Quality of Life After Adjuvant Chemoradiation Therapy or Radiation Therapy Alone for High-Risk Endometrial Cancer in the Randomized PORTEC-3 TrialCathalijne C B Post, Stephanie M de Boer, Melanie E Powell, et al.
BMJ Open|February 16, 2025
Models of care and associated targeted implementation strategies for cancer survivorship support in Europe: a scoping review protocolGillian Prue, Johanna Czamanski-Cohen, Angelos P Kassianos, et al.
Pageof 72

Showing results (701-710 of 719) with videos related to

Sort By:
Pageof 72
The Lancet. Oncology|September 8, 2025
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): 10-year clinical outcomes and post-hoc analysis by molecular classification from a randomised phase 3 trialCathalijne C B Post, Stephanie M de Boer, Melanie E Powell, et al.
Science Immunology|January 30, 2021
Steroid-resistant human inflammatory ILC2s are marked by CD45RO and elevated in type 2 respiratory diseasesEsmee K van der Ploeg, Korneliusz Golebski, Menno van Nimwegen, et al.
European Journal of Cancer (Oxford, England : 1990)|May 2, 2021
Clinical characteristics of subsequent histologically confirmed meningiomas in long-term childhood cancer survivors: A Dutch LATER studyLisanne C Verbruggen, Judith L Kok, Jop C Teepen, et al.
The Lancet. Oncology|May 3, 2024
Prognostic impact and causality of age on oncological outcomes in women with endometrial cancer: a multimethod analysis of the randomised PORTEC-1, PORTEC-2, and PORTEC-3 trialsFamke C Wakkerman, Jiqing Wu, Hein Putter, et al.
The Lancet. Oncology|February 17, 2018
Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trialStephanie M de Boer, Melanie E Powell, Linda Mileshkin, et al.
Journal of Occupational Rehabilitation|September 4, 2020
Effectiveness of a Tailored Work-Related Support Intervention for Patients Diagnosed with Gastrointestinal Cancer: A Multicenter Randomized Controlled TrialA C G N M Zaman, K M A J Tytgat, J H G Klinkenbijl, et al.
The Lancet. Oncology|July 27, 2019
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trialStephanie M de Boer, Melanie E Powell, Linda Mileshkin, et al.
Nature Medicine|April 15, 2026
An acetylated Tau-174 CSF biomarker discriminates between TDP-43 and tau pathology in patients with frontotemporal lobar degenerationMadison I J Honey, Yanaika S Hok-A-Hin, Elisabeth H Thijssen, et al.
International Journal of Radiation Oncology, Biology, Physics|November 1, 2020
Long-Term Toxicity and Health-Related Quality of Life After Adjuvant Chemoradiation Therapy or Radiation Therapy Alone for High-Risk Endometrial Cancer in the Randomized PORTEC-3 TrialCathalijne C B Post, Stephanie M de Boer, Melanie E Powell, et al.
BMJ Open|February 16, 2025
Models of care and associated targeted implementation strategies for cancer survivorship support in Europe: a scoping review protocolGillian Prue, Johanna Czamanski-Cohen, Angelos P Kassianos, et al.
Pageof 72